OTRA - OTRA STOCK NEWS

Comera Life Sciences announced that Robert P. Mahoney, Ph.D., the Chief Scientific Officer, will present at the PEGS Boston Conference & Expo from May 2-6, 2022. He will discuss an innovative caffeine-based excipient that effectively reduces the viscosity of monoclonal antibodies without compromising their stability. The presentation is scheduled for May 4, 2022, from 1:00 to 1:30 PM ET at the Hynes Convention Center in Boston. This advancement could significantly enhance patient access to biologic therapies through self-administration options.

Comera Life Sciences and Intas Pharmaceuticals have announced a research collaboration focused on developing innovative biologic medicines. This partnership will leverage Comera's proprietary SQore™ formulation platform to create a differentiated formulation of an Intas product. Intas will provide initial research funding, with an option to acquire global rights to the formulation. Both companies aim to enhance patient access and improve treatment outcomes, contributing to healthcare savings. This partnership reflects Comera's strategy to transition from preclinical to marketed products.

OTR Acquisition Corp. has announced a special meeting for stockholders on May 10, 2022, to discuss the proposed business combination with Comera Life Sciences. The Securities and Exchange Commission has declared the Registration Statement on Form S-4 effective. A definitive proxy statement/prospectus will be filed by April 15, 2022. This merger aims to enhance patient access to biologic medicines by transforming IV medications to subcutaneous forms.

OTR Acquisition Corp. (NASDAQ: OTRAU, OTRA, OTRAW) has rescheduled its investor call to February 8, 2022, at 8:30 a.m. EST, to discuss its proposed business combination with Comera Life Sciences, Inc.. The SEC has received a confidential draft registration statement related to this deal, which aims to transform IV biologic medicines into self-injectable SQ forms. The merger reflects a strategic move towards enhancing patient care and reducing institutional dependency.

Brodsky & Smith announces investigations concerning potential breaches of fiduciary duties by the boards of Angel Pond Holdings (NYSE: POND), OTR Acquisition Corp (Nasdaq: OTRA), and Agrico Acquisition Corp (Nasdaq: RICO) related to their SPAC mergers. Specifically, the investigations focus on whether fair processes were conducted, especially regarding shareholder ownership dilution in the resultant public companies. Angel Pond shareholders will retain 27%, OTR shareholders 41.1%, and Agrico shareholders 42% or less of their respective combined entities.

Comera Life Sciences and OTR Acquisition Corp. have announced a business combination, intending to create an entity valued at approximately $258.4 million. The transaction aims to enhance patient access to biologic medicines by transitioning from intravenous to subcutaneous administration, utilizing Comera's SQore™ formulation platform. The combined companies expect to generate around $107 million in gross proceeds from the merger, which is anticipated to finalize in Q2 2022, subject to shareholder approval.